Beacon is investigating the gene therapy in other pivotal trials, including the VISTA trial that is expected to readout in H2 2026.

Gene Therapeutics has reported additional interim outcomes from its ongoing LEGEND Phase II trial assessing detalimogene voraplasmid for BCG-unresponsive NMIBC.

ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.

MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early HER2-positive breast cancer.

Credit: Stig Alenas / Shutterstock.com Moderna’s mRNA flu vaccine has proved to be more effective than a standard flu vaccine in a Phase III trial. In the study (NCT06602024), which enrolled more than ...

Taimei Technology and South Korea’s C&R Research have partnered to co-develop an AI-powered clinical trial operations system.

Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial of AP301 for hyperphosphatemia.

Kyowa Kirin and Kura Oncology have begun a Japanese Phase II registrational study of ziftomenib in adult patients with r/r NPM1-mutated AML.

Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE study assessing taplucainium as a treatment for rCC/uCC.

Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those who received placebo.

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.